Skip to main content

Peer Review reports

From: Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

Original Submission
22 Dec 2023 Submitted Original manuscript
24 Jan 2024 Reviewed Reviewer Report
30 Jan 2024 Reviewed Reviewer Report
27 Feb 2024 Author responded Author comments - Todor I. Totev
Resubmission - Version 2
27 Feb 2024 Submitted Manuscript version 2
19 Mar 2024 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
24 Mar 2024 Editorially accepted
27 Mar 2024 Article published 10.1186/s12885-024-12178-w

You can find further information about peer review here.

Back to article page